pH4HIF | Effect of pH on colloidal structures in human intestinal fluids and intestinal absorption of anticancer drugs

Summary
Oral administration followed by intestinal absorption is the preferred way to deliver drugs to the body. Therefore, estimating the
correct oral dose to achieve a therapeutic effect is an important challenge when developing drug products. Predicting intestinal drug
absorption needs to consider multiple influencing factors, including properties of the drug, the formulation, and the human intestinal
fluids (HIF). One of the critical factors of HIF is pH, as it may influence intestinal drug absorption both directly and indirectly. The direct
effect of pH on a drug’s ionisation state and, subsequently, intestinal absorption is widely known. However, the effect of pH on the
solubilisation and absorption of lipophilic drugs by changing the colloidal structures present in HIF, has not yet been systematically
analysed.

Understanding this indirect pH effect is especially needed to improve dose predictions for drugs with a narrow therapeutic window
such as anticancer drugs, and address both inefficiency and potential side effects. The proposed project therefore aims to understand
and predict the pH effect on colloidal structures in HIF and how it affects the absorption potential of anticancer drugs in both fasted
and fed state conditions.

To achieve its goal, the project combines the expertise of the host group at KU Leuven in absorption profiling using in vitro and in
vivo methods with the applicant’s experience in predictive in silico modelling. This approach will provide unique insights into the
indirect pH effect on drug absorption and contribute to the development of in silico predictive models to guide the early-stage
formulation and dose optimisation of anticancer drugs. As such, the project will have important value for pipelining new anticancer
drugs and will benefit the European Commission priorities for 2019-2024, such as the pharmaceutical strategy and Europe’s Beating
Cancer Plan.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101108993
Start date: 01-09-2023
End date: 31-08-2025
Total budget - Public funding: - 175 920,00 Euro
Cordis data

Original description

Oral administration followed by intestinal absorption is the preferred way to deliver drugs to the body. Therefore, estimating the
correct oral dose to achieve a therapeutic effect is an important challenge when developing drug products. Predicting intestinal drug
absorption needs to consider multiple influencing factors, including properties of the drug, the formulation, and the human intestinal
fluids (HIF). One of the critical factors of HIF is pH, as it may influence intestinal drug absorption both directly and indirectly. The direct
effect of pH on a drug’s ionisation state and, subsequently, intestinal absorption is widely known. However, the effect of pH on the
solubilisation and absorption of lipophilic drugs by changing the colloidal structures present in HIF, has not yet been systematically
analysed.

Understanding this indirect pH effect is especially needed to improve dose predictions for drugs with a narrow therapeutic window
such as anticancer drugs, and address both inefficiency and potential side effects. The proposed project therefore aims to understand
and predict the pH effect on colloidal structures in HIF and how it affects the absorption potential of anticancer drugs in both fasted
and fed state conditions.

To achieve its goal, the project combines the expertise of the host group at KU Leuven in absorption profiling using in vitro and in
vivo methods with the applicant’s experience in predictive in silico modelling. This approach will provide unique insights into the
indirect pH effect on drug absorption and contribute to the development of in silico predictive models to guide the early-stage
formulation and dose optimisation of anticancer drugs. As such, the project will have important value for pipelining new anticancer
drugs and will benefit the European Commission priorities for 2019-2024, such as the pharmaceutical strategy and Europe’s Beating
Cancer Plan.

Status

SIGNED

Call topic

HORIZON-MSCA-2022-PF-01-01

Update Date

31-07-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.1 Excellent Science
HORIZON.1.2 Marie Skłodowska-Curie Actions (MSCA)
HORIZON.1.2.0 Cross-cutting call topics
HORIZON-MSCA-2022-PF-01
HORIZON-MSCA-2022-PF-01-01 MSCA Postdoctoral Fellowships 2022